Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Res ; 65(20): 9377-87, 2005 Oct 15.
Article in English | MEDLINE | ID: mdl-16230401

ABSTRACT

Matrix metalloproteinase (MMP)-2 and its hemopexin C domain autolytic fragment (also called PEX) have been proposed to be crucial for angiogenesis. Here, we have investigated the dependency of in vitro angiogenesis on MMP-mediated extracellular proteolysis and integrin alpha(v)beta3-mediated cell adhesion in a three-dimensional collagen I model. The hydroxamate-based synthetic inhibitors BB94, CT1399, and CT1847 inhibited endothelial cell invasion, as did neutralizing anti-membrane-type 1-MMP (MT1-MMP) antibodies and tissue inhibitor of MMP (TIMP)-2 and TIMP-3 but not TIMP-1. This confirmed the pivotal importance of MT1-MMP over other MMPs in this model. Invasion was also inhibited by a nonpeptidic antagonist of integrin alpha(v)beta3, EMD 361276. Although PEX strongly inhibited pro-MMP-2 activation, when contaminating lipopolysaccharide was neutralized, PEX neither affected angiogenesis nor bound integrin alpha(v)beta(3). Moreover, no specific binding of pro-MMP-2 to integrin alpha(v)beta3 was found, whereas only one out of four independently prepared enzymatically active MMP-2 preparations could bind integrin alpha(v)beta3 , and this in a PEX-independent manner. Likewise, integrin alpha(v)beta3 -expressing cells did not bind MMP-2-coated surfaces. Hence, these findings show that endothelial cell invasion of collagen I gels is MT1-MMP and alpha(v)beta3 - dependent but MMP-2 independent and does not support a role for PEX in alpha(v)beta3 integrin binding or in modulating angiogenesis in this system.


Subject(s)
Hemopexin/metabolism , Integrin alphaVbeta3/metabolism , Matrix Metalloproteinase 2/metabolism , Metalloendopeptidases/metabolism , Neovascularization, Physiologic/physiology , Animals , Cattle , Cytokines/pharmacology , Endothelial Cells/enzymology , Endothelial Cells/metabolism , Enzyme Activation , Fibroblast Growth Factor 2/pharmacology , Hemopexin/pharmacology , Humans , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 2/pharmacology , Matrix Metalloproteinases, Membrane-Associated , Metalloendopeptidases/antagonists & inhibitors , Metalloendopeptidases/biosynthesis , Oligopeptides/pharmacology , Protein Structure, Tertiary , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Vascular Endothelial Growth Factor A/pharmacology
2.
Biol Reprod ; 66(1): 144-58, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11751276

ABSTRACT

During the reproductive cycle, ovarian follicles undergo major tissue-remodeling involving vascular changes and proteolysis. Anticoagulant heparan sulfate proteoglycans (aHSPGs) are expressed by granulosa cells during the development of the ovarian follicle. The function of aHSPGs in the ovary is unknown, but they might be involved in proteolysis control through binding and activation of serine protease inhibitors. To identify functional interactions between aHSPGs and heparin-binding protease inhibitors in the follicle, we have coordinately localized aHSPGs, antithrombin III, protease nexin-1, and plasminogen activator inhibitor-1 in the rat ovary during natural and gonadotropin-stimulated cycles. Anticoagulant HSPGs were visualized by autoradiography of cryosections incubated with 125I-antithrombin III, and protease inhibitors were assessed by immunohistochemistry and Northern blot hybridization. Anticoagulant HSPGs were expressed in follicles before ovulation, were transiently decreased in postovulatory follicles, and were abundant in the corpus luteum, mainly on capillaries. Anticoagulant HSPGs were colocalized with protease nexin-1 in follicles from the early antral stage until ovulation, with antithrombin III in the preovulatory stage and after ovulation, and with plasminogen activator inhibitor-1 in the corpus luteum. These data demonstrate that aHSPGs are critically expressed in the ovary to interact sequentially with protease nexin-1, antithrombin III, and plasminogen activator inhibitor-1 during the cycle. The specificity of these inhibitors is shifted toward thrombin inhibition in the presence of heparin, suggesting that aHSPGs direct their action to control fibrin deposition in the follicle. The occupation of aHSPGs antithrombin-binding sites by mutant R393C antithrombin III, injected in the ovarian bursa, decreased ovulation efficiency, further supporting the involvement of aHSPGs in the ovulation process.


Subject(s)
Anticoagulants/blood , Heparan Sulfate Proteoglycans/biosynthesis , Heparan Sulfate Proteoglycans/physiology , Ovary/metabolism , Serine Proteinase Inhibitors/biosynthesis , Amyloid beta-Protein Precursor , Animals , Blotting, Northern , Carrier Proteins/metabolism , Cell Line , Cricetinae , Estrous Cycle/physiology , Female , Fibrin/metabolism , Granulosa Cells/metabolism , Immunohistochemistry , Ovulation/physiology , Plasminogen Activator Inhibitor 1/biosynthesis , Protease Nexins , RNA/isolation & purification , Rats , Rats, Sprague-Dawley , Receptors, Cell Surface , Serpins/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...